Abstract:The determination of metabolic stability is critical for drug discovery programs, allowing for the optimization of chemical entities and compound prioritization. As such, it is common to perform high-volume in vitro metabolic stability experiments early in the lead optimization process to understand metabolic liabilities. Additional metabolite identification experiments are subsequently performed for a more comprehensive understanding of the metabolic clearance routes to aid medicinal chemists in the structural design of compounds. Collectively, these experiments require extensive sample preparation and a substantial amount of time and resources. To overcome the challenges, a high-throughput integrated assay for simultaneous hepatocyte metabolic stability assessment and metabolite profiling was developed. This assay platform consists of four parts: 1) an automated liquid-handling system for sample preparation and incubation, 2) a liquid chromatography and high-resolution mass spectrometry-based system to simultaneously monitor the parent compound depletion and metabolite formation, 3) an automated data analysis and report system for hepatic clearance assessment; and 4) streamlined autobatch processing for software-based metabolite profiling. The assay platform was evaluated using eight control compounds with various metabolic rates and biotransformation routes in hepatocytes across three species. Multiple sample preparation and data analysis steps were evaluated and validated for accuracy, repeatability, and metabolite coverage. The combined utility of an automated liquid-handling instrument, a high-resolution mass spectrometer, and multiple streamlined data processing software improves the process of these highly demanding screening assays and allows for simultaneous determination of metabolic stability and metabolite profiles for more efficient lead optimization during early drug discovery. SIGNIFICANCE STATEMENT: Metabolic stability assessment and metabolite profiling are pivotal in drug discovery to fully comprehend metabolic liabilities for chemical entity optimization and lead selection. Process of these assays can be repetitive and resource demanding. Here, we developed an integrated hepatocyte stability assay that combines automation, high-resolution mass spectrometers, and batch-processing software to improve and combine the workflow of these assays. The integrated approach allows simultaneous metabolic stability assessment and metabolite profiling, significantly accelerating screening and lead optimization in a resource-effective manner.

Biotechnological synthesis of drug metabolites using P 450-expressing fission yeast – new perspectives in metabolism studies for 4 ’ methyl-a-pyrrolidinobutyrophenone

Biotechnological Synthesis of Drug Metabolites Using Human Cytochrome P450 2d6 Heterologously Expressed in Fission Yeast Exemplified for the Designer Drug Metabolite 4 '-Hydroxymethyl-alpha-pyrrolidinobutyrophenone

Biotechnological Synthesis of Drug Metabolites Using Human Cytochrome P450 Isozymes Heterologously Expressed in Fission Yeast

Biotechnological Synthesis Of Drug Metabolites Using Human Cytochrome P450 Isozymnes Heterologously Expressed In Fission Yeast

Biotechnological Synthesis of the Designer Drug Metabolite 4'-Hydroxymethyl-alpha-pyrrolidinohexanophenone in Fission Yeast Heterologously Expressing Human Cytochrome P450 2D6--a Versatile Alternative to Multistep Chemical Synthesis.

Precision Biotransformation of Emerging Pollutants by Human Cytochrome P450 Using Computational–Experimental Synergy: A Case Study of Tris(1,3-dichloro-2-propyl) Phosphate

Convenient Gram-Scale Metabolite Synthesis by Engineered Fission Yeast Strains Expressing Functional Human P450 Systems

Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine

Isolation and Purification of the Desig- ner Drug Metabolite O-Desethyl-N- (1-phenylcyclohexyl)-3-ethoxy- propanamine (O-Desethyl-PCEPA) Biotechnologically Synthesized using Fission Yeast Expressing CYP2D6

Experimental and Computational Studies on the Biotransformation of Pseudopyronines with Human Cytochrome P450 CYP4F2

Biocatalysis using Thermostable Cytochrome P450 Enzymes in Bacterial Membranes - Comparison of Metabolic Pathways with Human Liver Microsomes and Recombinant Human Enzymes

Glucuronide production by whole-cell biotransformation using genetically engineered fission yeast Schizosaccharomyces pombe.

Production of Human Phase 1 and 2 Metabolites by Whole-Cell Biotransformation with Recombinant Microbes

Design, Synthesis, and Phenotypic Profiling of Pyrano‐Furo‐Pyridone Pseudo Natural Products

An Integrated Hepatocyte Stability Assay for Simultaneous Metabolic Stability Assessment and Metabolite Profiling

Selective P450<sub>BM3</sub> Hydroxylation of Cyclobutylamine and Bicyclo[1.1.1]pentylamine Derivatives: Underpinning Synthetic Chemistry for Drug Discovery

Rapid and Convenient Biotransformation Procedure for Human Drug Metabolizing Enzymes Using Permeabilized Fission Yeast Cells

Pyrrolidinyl Synthetic Cathinones α-PHP and 4F-α-PVP Metabolite Profiling Using Human Hepatocyte Incubations

Expanding the Scope of Targeted Metabolomics by One-pot Microscale Synthesis and Tailored Metabolite Profiling: Investigation of Bile Acid-Amino Acid Conjugates.

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design

A Metabolomics Footprinting Approach using GC-MS to Study Inhibitory Effects of the Fungal Metabolite Diplopyrone C against Nosocomial Pathogen Biofilms